CME
Andexanet Alfa Is Associated With Lower In-Hospital Mortality Compared to 4-Factor Prothrombin Complex Concentrate in Patients With Factor Xa Inhibitor–Related Major Bleeding
July 28, 2023
Host: Paul P. Dobesh, PharmD, FACC, FAHA, FCCP, BCPS, BCCP Patients presenting to the hospital with severe bleeding and underlying treatment with Factor Xa (FXa) or Factor IIa inhibitors represent an enormous challenge to providers and clinician
Visit Podcast Website
RSS Podcast Feed
Subscribe
Share
Add to MyCast
Gain access to Blubrry tools that help build your podcast, including free podcast stats!